Pharma
-
Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Sanofi and Regeneron both scored in the rare disease space while Lilly's dealmaking streak continued.
By PharmaVoice Staff • Nov. 19, 2026 -
3 standout drug launches of 2026 and what comes next
New drugs from Revolution, J&J and Vera are off to the races, putting different commercial strategies to the test.
By Sy Mukherjee • Nov. 19, 2026 -
Explore the Trendline➔
Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
GLP-1s are being tied to unusual side effects — but are they to blame?
Reports of hair loss, nail detachment and vision problems highlight a persistent challenge for drug safety monitoring.
By Kelly Bilodeau • Nov. 18, 2026 -
Making Moves
J&J, Novartis vet to lead Gates MRI amid TB vaccine push
After a long career in vaccines and global health, Krishnan Ramanathan officially takes the helm at the nonprofit as its tuberculosis and RSV candidates advance through the clinic.
By Meagan Parrish • Nov. 18, 2026 -
Pharma’s embraced AI. Who’s keeping it in check?
A new survey reveals gaps in pharma’s internal oversight of AI and confusion over accountability.
By Alexandra Pecci • Nov. 17, 2026 -
Overton’s iffy FDA confirmation; a slashed US IPO
The clock is ticking on Dr. Heidi Overton’s confirmation as FDA commissioner; investors didn’t give a Swiss dental health company the deal it wanted.
By PharmaVoice Staff • Nov. 13, 2026 -
3 quotes that show why MAHA is cheering Stephen Miller’s ascension
Miller is no friend of pharma’s and he just landed one of the most powerful roles in Washington.
By Meagan Parrish • Nov. 13, 2026 -
The FDA has over 1k open jobs — and the staffing shortage is hitting pharma
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
By Kelly Bilodeau • Nov. 11, 2026 -
Making Moves
Pfizer’s comeback gets a new finance chief
Cecile Guegan just became Pfizer’s first permanent female CFO as the large pharma navigates its major pipeline bets in obesity.
By Meagan Parrish • Nov. 10, 2026 -
Sponsored by Cytiva
How can we build trust in model-driven manufacturing?
Predict, optimize and act sooner with model-driven bioprocessing.
By Martin Ball, Senior Product Marketing Manager, Automation and Digital, Cytiva • Nov. 9, 2026 -
The end of MAHA?; Inovio’s big FDA win
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.
By PharmaVoice Staff • Nov. 6, 2026 -
The Democrats are coming. Here’s how they want to change pharma and healthcare.
This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling back the curtain on Trump’s secretive pharma deals.
By Meagan Parrish • Nov. 5, 2026 -
Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped
While its GLP-1 franchise is still booming, prospects in other arenas haven’t panned out. Here’s a look at where Lilly’s investing the candidates it’s recently had to drop.
By Kelly Bilodeau • Nov. 3, 2026 -
Q&A
How well is J&J’s incubator model working?
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
By Meagan Parrish • Nov. 2, 2026 -
Sponsored by Evonik
Making oral drug delivery more sustainable with measurable product-level data
How auditable LCA data can guide more informed sustainability decisions.
Nov. 2, 2026 -
Keytruda biosims are coming — but they face an uphill battle
The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
By Kelly Bilodeau • Oct. 30, 2026 -
Anthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
By PharmaVoice Staff • Oct. 30, 2026 -
Pharma has friends in both parties this midterm season. Neither is offering a free pass.
As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could complicate its traditional campaign playbook.
By Sy Mukherjee • Oct. 29, 2026 -
Court rejects Novo bid to block Lilly obesity drug ads
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
By Jonathan Gardner • Oct. 28, 2026 -
A cancer drug worked in the lab — but not how scientists thought
Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.
By Kelly Bilodeau • Oct. 23, 2026 -
Most new drugs are still too costly at launch, ICER says
A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
By Jonathan Gardner • Oct. 22, 2026 -
Drug discovery is speeding up. But clinical trials are buckling under their own weight.
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
By Sy Mukherjee • Oct. 22, 2026 -
Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.
By Alexandra Pecci • Oct. 20, 2026 -
Q&A
Alzheimer’s trials need patients. Why are so many screened out?
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
By Kelly Bilodeau • Oct. 16, 2026 -
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
By Sy Mukherjee • Oct. 15, 2026